1-(2-(benzyloxy)-5-chlorobenzyl)-5-methyl-N-phenyl-1H-pyrazole-3-carboxamide

ID: ALA404698

Chembl Id: CHEMBL404698

PubChem CID: 44448598

Max Phase: Preclinical

Molecular Formula: C25H22ClN3O2

Molecular Weight: 431.92

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1cc(C(=O)Nc2ccccc2)nn1Cc1cc(Cl)ccc1OCc1ccccc1

Standard InChI:  InChI=1S/C25H22ClN3O2/c1-18-14-23(25(30)27-22-10-6-3-7-11-22)28-29(18)16-20-15-21(26)12-13-24(20)31-17-19-8-4-2-5-9-19/h2-15H,16-17H2,1H3,(H,27,30)

Standard InChI Key:  UOLPNGSLHSUNBF-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA404698

   1-[(5-chloro-2-phenylmethoxyphenyl)methyl]-5-methyl-N-phenylpyrazole-3-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 431.92

Molecular Weight (Monoisotopic): 431.1401

AlogP: 5.72

#Rotatable Bonds: 7

Polar Surface Area: 56.15

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 0.21

CX LogP: 5.97

CX LogD: 5.97

Aromatic Rings: 4

Heavy Atoms: 31

QED Weighted: 0.41

Np Likeness Score: -1.93

References

1. Hall A, Billinton A, Brown SH, Clayton NM, Chowdhury A, Giblin GM, Goldsmith P, Hayhow TG, Hurst DN, Kilford IR, Naylor A, Passingham B, Winyard L..  (2008)  Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.,  18  (11): [PMID:18462938] [10.1016/j.bmcl.2008.04.018]

2. Hall A, Billinton A, Bristow AK, Brown SH, Chowdhury A, Cutler L, Giblin GM, Goldsmith P, Hayhow TG, Kilford IR, Naylor A, Passingham B, Rawlings DA..  (2008)  Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists.,  18  (14): [PMID:18571922] [10.1016/j.bmcl.2008.05.118]

3. Das B, Baidya ATK, Mathew AT, Yadav AK, Kumar R..  (2022)  Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,  56  [PMID:35033884] [10.1016/j.bmc.2022.116614]

Source

Source(1):

• Scientific Literature